The University of Texas MD Anderson Cancer Center
Overview
The University of Texas MD Anderson Cancer Center is a comprehensive cancer research and treatment institution that operates as a strategic investor in biotechnology companies and collaborates with investment funds like the Cancer Focus Fund to advance oncology therapies.
Investments
| Company | Date | Stage | Lead |
|---|---|---|---|
| Starget Pharma | Feb 2026 | Series A | - |
| March Biosciences | Oct 2024 | Series A | - |
| Starget Pharma | Oct 2024 | Seed | - |
| Eisbach Bio GmbH | Mar 2024 | VC Round | - |
| March Biosciences | Nov 2023 | VC Round | - |
Key People
Tanya Gibbons
Managing Director
Cassian Yee
T Cells in Space a CASIS NASA funded oroject to study effects of microgravity on T cell fate, Professor, Melanoma Medical Oncology, Professor, Department of Immunology, Director, Solid Tumor Cell Therapy
Chachere R
Principal Project Manager
EDAC Erica Parker
Innovation Principal
Edith Nagy
Principal Scientist
Natenael Semmineh
Principal Research Scientist
Otto Akers
Principal Safety Specialist
Sreedhar Mandayam
Professor, Principal Investigator
Tony Benedetto
Principal
Sector & Stage Mix
Industry, funding stage, and valuation band breakdowns.
